Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 10, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] Group 3: Case Background - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, during its IPO, stating there were no safety concerns and expecting positive trial results [5] - BioAge discontinued the STRIDES Phase 2 study of azelaprag after subjects showed elevated liver enzyme levels, which were not disclosed in prior trials, leading to claims that the company's statements were false and misleading [6]
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit